NeoGenomics Liquid Biopsy Subsidiary Inivata and Collaborators Publish Positive Results from Prospective Clinical Study of RaDaR(TM) in Head and Neck Squamous Cell CarcinomaAccesswire • 02/11/22
NeoGenomics to Participate Virtually in Multiple Upcoming Institutional Investor ConferencesAccesswire • 02/08/22
NeoGenomics Schedules its Fourth Quarter and Full Year 2021 Earnings Release for February 23, 2022Accesswire • 02/02/22
NeoGenomics First to Partner with Biomarker Collaborative and Deliver Patient Resources Along with Oncology Testing ResultsAccesswire • 01/24/22
NeoGenomics Announces RaDaR(TM) Assay Receives CE Mark and is Submitted for US Reimbursement via the MolDX ProgramAccesswire • 01/11/22
Inivata Announces RaDaR™ Assay Receives CE Mark and is Submitted for US Reimbursement via the MolDX ProgramGlobeNewsWire • 01/11/22
NeoGenomics Appoints David Eberhard MD, PhD as Chief Medical Officer of Inivata Liquid Biopsy SubsidiaryAccesswire • 12/13/21
NeoGenomics to Leverage Thermo Fisher Scientific's Ion Torrent Genexus System in Upcoming Phase 1 Study for Myeloid CancersAccesswire • 12/10/21
NeoGenomics, Inc.'s (NEO) CEO Mark Mallon on Q3 2021 Results - Earnings Call TranscriptSeeking Alpha • 11/04/21
Inivata Announces Clinical Collaboration with Princess Margaret Cancer Center for the use of its Liquid Biopsy AssaysGlobeNewsWire • 10/19/21
NeoGenomics' Liquid Biopsy Subsidiary Inivata Announces Clinical Collaboration With Princess Margaret Cancer Center for the Use of Its Liquid Biopsy AssaysAccesswire • 10/19/21
NeoGenomics Schedules its Third Quarter 2021, Earnings Release for November 4, 2021Accesswire • 10/13/21
NeoGenomics' Liquid Biopsy Subsidiary Inivata and Collaborators to Present Data that Further Validate the Application of its RaDaR(TM) MRD and InVisionFirst(R)-Lung Assays at the ESMO Congress 2021Accesswire • 09/09/21